Difference Expressions CD34 in Acute Myeloid Leukemia Cell Culture in the Administration of Cytarabine-Daunorubicine Dose Standards

Authors

  • Muhammad Saiful Rahman Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya
  • Paulus Budiono Notopuro Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya
  • Suprapto Ma'at Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya
  • Made Putra Sedana Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya
  • Arifoel Hajat Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

DOI:

https://doi.org/10.24293/ijcpml.v27i2.1623

Keywords:

Acute myeloid leukemia, CD34, cytarabine-daunorubicine, flow cytometry

Abstract

The cure rate for patients with Acute Myeloid Leukemia (AML) is 20-75%. Standard-dose cytarabine + (SDAC)-daunorubicine gives a remission rate of ± 60%, and the case of relapse is frequently found. In-vivo CD34 expression is a reliable and straightforward test that must evaluate AML patients' response to predict the response of chemotherapy + induction phase accurately. Differences in in-vitro CD34 expression are expected to be able to predict chemosensitivity in AML patients. An experimental post-test-only control group study was conducted from May to December 2019, and 8 AML subjects were found. Peripheral Blood Mononuclear Cells (PBMC) were isolated from peripheral blood samples of patients with AML collected in EDTA tubes. The PBMC isolated from peripheral blood were divided into two groups, and each group contained 106 PBMC cells in culture media. The control group (without treatment) and the SDAC-daunorubicine group were 0 + incubated for 4 hours at 37 C with a 5% CO2 atmosphere. The expression of CD34 was measured using FACSCaliburâ„¢, while + CD34+ percentage was calculated with CellQuestâ„¢ software. The percentage of CD34 in the control, SDAC + DNR, showed a significant difference with p < 0.001. This study showed a significant difference between the control group and the group + administered with the standard dose of cytarabine-daunorubicine with p < 0.001. The average CD34 expression in the + SDAC-DNR treatment group was higher than in the control group. CD34 markers cannot be used as predictors of chemosensitivity in the administration of chemotherapy.

Downloads

Download data is not yet available.

Author Biographies

Muhammad Saiful Rahman, Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Paulus Budiono Notopuro, Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Suprapto Ma'at, Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Made Putra Sedana, Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Arifoel Hajat, Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

References

Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of acute

myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the

European Leukemia Net. Blood, 2010; 115(3): 453-474.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin, 2018; 68(6): 394-424.

Novilla A. Thesis aktivitas dan mekanisme molekuler antikanker in-vitro senyawa turunan kalkon terhadap sel lini mieloid HL60 dan K562. Biosience Research, 2017; 2011: 731-740.

Murphy T, Yee KWL. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert Opin. Pharmacother, 2017; 18(16): 1765-1780.

Wu D, Duan C, Chen L, Chen S. Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: A network meta-analysis. Sci. Rep, 2017; 7(1): 1-10.

Ma'at S. Kultur sel. Teknik dasar kultur sel. 1 Ed., Surabaya, Airlangga University Press, 2011; 3-25.

Heasman SA, Zaitseva L, Bowles KM, Rushworth SA, MacEwan DJ. Protection of acute myeloid leukemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. Oncotarget, 2011; 2(9): 658-668.

Ersvaer E, Brenner AK, Vetås K, Reikvam H, Bruserud í˜.Effects of cytarabine on activation of human

T-cells-cytarabine has concentration-dependent effects that are modulated both by valproic acid and

all-trans retinoic acid. BMC Pharmacol Toxicol, 2015; 16(1): 1-16.

Maskito VJ, Notopuro PB, Ma'at S, Sedana MP. Karya akhir perbandingan indeks proliferasi kultur sel

lekemia mieloid akut setelah pemberian dosis standar sitarabin-daunorubisin, sitarabin dosis tinggi dan

azacitidine. Surabaya, 2019; 49-50.

O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw, 2017; 15(7): 926-957.

Rahmadin B, Wahid I, Yaswir R. Artikel penelitian profil penderita leukemia mieloblastik akut di bagian penyakit. J. Kesehat. Andalas, 2017; 6(3): 495-501.

WHO. Acute myelogenous leukemia (including acute promyelocytic leukemia). 2014 Rev. Cancer Med. (list of essential medicines), 2014; 1-14.

Blair HA. Daunorubicin/cytarabine liposome: A review in acute myeloid leukemia. Drugs, 2018; 78(18): 1903-1910.

Costello RT, Mallet F, Gaugler B, Sainty D, Arnoulet C, - et al. Human acute myeloid leukemia /Cd38

progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced

immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res, 2000; 60(16):

-4411.

Aramvash A, Chadegani AR, Lotfi S. Evaluation of apoptosis in multipotent hematopoietic cells of bone marrow by anthracycline antibiotics. Iran. J. Pharm.Res, 2017; 16(3): 1206-1215.

Downloads

Submitted

2020-02-02

Accepted

2020-12-18

Published

2021-04-15

How to Cite

[1]
Rahman, M.S., Notopuro, P.B., Ma’at, S., Sedana, M.P. and Hajat, A. 2021. Difference Expressions CD34 in Acute Myeloid Leukemia Cell Culture in the Administration of Cytarabine-Daunorubicine Dose Standards. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY. 27, 2 (Apr. 2021), 143–146. DOI:https://doi.org/10.24293/ijcpml.v27i2.1623.

Issue

Section

Articles